Management expects Triple-digit Percentage Revenue Growth sequentially for the Fiscal 2022 Third Quarter
BELLEVUE, Wash.–(BUSINESS WIRE)–$NVOS #Benzinga–Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended February 28, 2022.
Robert Mattacchione, Novo’s CEO and Board Chairman, stated, “The 38.2% year-over-year revenue growth we experienced for the fiscal second quarter is directly related to the expansion of our essential and differentiated ecosystem for the delivery of healthcare related services and products. The Company projects ‘triple-digit’ percentage revenue growth sequentially for the fiscal third quarter ending May 31, 2022 primarily due to product and diagnostic technology sales. This projected acceleration in revenue growth in future quarters is directly related to the effects of commercializing our three-pillar model and crystalizes the Company’s mission for a fully integrated healthcare ecosystem, with global reach, resulting in rapid growth and profitability.”
Financial Highlights for the Period Ended February 28, 2022:
Operational Milestones:
Operational Milestones Subsequent to End of Fiscal 2022 Second Quarter:
About Novo Integrated Sciences, Inc.
Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, diagnostic and therapeutic solutions, and rehabilitative science.
We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.
The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:
Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient first platforms.
For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com. For more information on Novo Healthnet Limited, Novo’s wholly owned subsidiary, please visit www.novohealthnet.com.
Twitter, LinkedIn, Facebook, Instagram, YouTube
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.
|
NOVO INTEGRATED SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of February 28, 2022 (unaudited) and August 31, 2021 |
||||||||
|
|
|
February 28, |
|
August 31, |
||||
|
|
|
2022 |
|
2021 |
||||
|
|
|
(unaudited) |
|
|
||||
|
ASSETS |
|
|
|
|
|
|
||
|
Current Assets: |
|
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
15,943,997 |
|
|
$ |
8,293,162 |
|
|
Accounts receivable, net |
|
|
1,251,973 |
|
|
|
1,468,429 |
|
|
Inventory |
|
|
334,414 |
|
|
|
339,385 |
|
|
Other receivables, current portion |
|
|
981,597 |
|
|
|
814,157 |
|
|
Prepaid expenses and other current assets |
|
|
503,437 |
|
|
|
218,376 |
|
|
Total current assets |
|
|
19,015,418 |
|
|
|
11,133,509 |
|
|
|
|
|
|
|
|
|
||
|
Property and equipment, net |
|
|
6,157,621 |
|
|
|
6,070,291 |
|
|
Intangible assets, net |
|
|
33,217,602 |
|
|
|
32,436,468 |
|
|
Right-of-use assets, net |
|
|
2,348,391 |
|
|
|
2,543,396 |
|
|
Other receivables, net of current portion |
|
|
522,062 |
|
|
|
692,738 |
|
|
Goodwill |
|
|
9,058,936 |
|
|
|
9,081,879 |
|
|
TOTAL ASSETS |
|
$ |
70,320,030 |
|
|
$ |
61,958,281 |
|
|
|
|
|
|
|
|
|
||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
Current Liabilities: |
|
|
|
|
|
|
||
|
Accounts payable |
|
$ |
1,105,707 |
|
|
$ |
1,449,784 |
|
|
Accrued expenses |
|
|
1,199,274 |
|
|
|
1,129,309 |
|
|
Accrued interest (including amounts to related parties) |
|
|
642,246 |
|
|
|
366,280 |
|
|
Government loans and notes payable, current portion |
|
|
5,260,047 |
|
|
|
4,485,649 |
|
|
Convertible notes payable, net of discount of $302,550 |
|
|
1,572,450 |
|
|
|
– |
|
|
Contingent liability |
|
|
749,626 |
|
|
|
– |
|
|
Due to related parties |
|
|
473,367 |
|
|
|
478,920 |
|
|
Finance lease liability, current portion |
|
|
17,533 |
|
|
|
23,184 |
|
|
Operating lease liability, current portion |
|
|
533,535 |
|
|
|
530,797 |
|
|
Total current liabilities |
|
|
11,553,785 |
|
|
|
8,463,923 |
|
|
|
|
|
|
|
|
|
||
|
Debentures, related parties |
|
|
979,724 |
|
|
|
982,205 |
|
|
Notes payable, net of current portion |
|
|
174,242 |
|
|
|
5,133,604 |
|
|
Convertible notes payable, net of discount of $6,943,704 |
|
|
9,722,962 |
|
|
|
– |
|
|
Finance lease liability, net of current portion |
|
|
10,854 |
|
|
|
16,217 |
|
|
Operating lease liability, net of current portion |
|
|
1,866,858 |
|
|
|
2,057,805 |
|
|
Deferred tax liability |
|
|
1,496,581 |
|
|
|
1,500,372 |
|
|
TOTAL LIABILITIES |
|
|
25,805,006 |
|
|
|
18,154,126 |
|
|
|
|
|
|
|
|
|
||
|
Commitments and contingencies |
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
||
|
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
|
Novo Integrated Sciences, Inc. |
|
|
|
|
|
|
||
|
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at February 28, 2022 and August 31, 2021, respectively |
|
|
|
|
|
|
||
|
Common stock; $0.001 par value; 499,000,000 shares authorized; 28,885,144 and 26,610,144 shares issued and outstanding at February 28, 2022 and August 31, 2021, respectively |
|
|
28,885 |
|
|
|
26,610 |
|
|
Additional paid-in capital |
|
|
60,691,723 |
|
|
|
54,579,396 |
|
|
Common stock to be issued (4,359,841 and 3,622,199 shares at February 28, 2022 and August 31, 2021) |
|
|
10,409,457 |
|
|
|
9,236,607 |
|
|
Other comprehensive income |
|
|
1,002,282 |
|
|
|
991,077 |
|
|
Accumulated deficit |
|
|
(27,581,028 |
) |
|
|
(20,969,274 |
) |
|
Total Novo Integrated Sciences, Inc. stockholders’ equity |
|
|
44,551,319 |
|
|
|
43,864,416 |
|
|
Noncontrolling interest |
|
|
(36,295 |
) |
|
|
(60,261 |
) |
|
Total stockholders’ equity |
|
|
44,515,024 |
|
|
|
43,804,155 |
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
70,320,030 |
|
|
$ |
61,958,281 |
|
|
NOVO INTEGRATED SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the Three and Six Months Ended February 28, 2022 and 2021 (unaudited) |
||||||||||||||||
|
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
|
February 28, |
|
February 28, |
|
February 28, |
|
February 28, |
||||||||
|
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||
|
|
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Revenues |
|
$ |
2,869,223 |
|
|
$ |
2,075,894 |
|
|
$ |
6,031,150 |
|
|
$ |
4,231,400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cost of revenues |
|
|
1,652,869 |
|
|
|
1,324,448 |
|
|
|
3,548,330 |
|
|
|
2,668,504 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Gross profit |
|
|
1,216,354 |
|
|
|
751,446 |
|
|
|
2,482,820 |
|
|
|
1,562,896 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Selling expenses |
|
|
26,370 |
|
|
|
602 |
|
|
|
26,538 |
|
|
|
1,845 |
|
|
General and administrative expenses |
|
|
3,310,660 |
|
|
|
2,076,788 |
|
|
|
5,940,617 |
|
|
|
3,644,719 |
|
|
Total operating expenses |
|
|
3,337,030 |
|
|
|
2,077,390 |
|
|
|
5,967,155 |
|
|
|
3,646,564 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Loss from operations |
|
|
(2,120,676 |
) |
|
|
(1,325,944 |
) |
|
|
(3,484,335 |
) |
|
|
(2,083,668 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Non operating income (expense) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Interest income |
|
|
8,490 |
|
|
|
8,301 |
|
|
|
16,878 |
|
|
|
16,863 |
|
|
Interest expense |
|
|
(1,226,182 |
) |
|
|
(22,948 |
) |
|
|
(1,294,912 |
) |
|
|
(46,889 |
) |
|
Amortization of debt discount |
|
|
(1,463,022 |
) |
|
|
– |
|
|
|
(1,520,862 |
) |
|
|
– |
|
|
Foreign currency transaction losses |
|
|
(66,814 |
) |
|
|
– |
|
|
|
(401,368 |
) |
|
|
– |
|
|
Total other income (expense) |
|
|
(2,747,528 |
) |
|
|
(14,647 |
) |
|
|
(3,200,264 |
) |
|
|
(30,026 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Loss before income taxes |
|
|
(4,868,204 |
) |
|
|
(1,340,591 |
) |
|
|
(6,684,599 |
) |
|
|
(2,113,694 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income tax expense |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net loss |
|
$ |
(4,868,204 |
) |
|
$ |
(1,340,591 |
) |
|
$ |
(6,684,599 |
) |
|
$ |
(2,113,694 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net loss attributed to noncontrolling interest |
|
|
(63,037 |
) |
|
|
(721 |
) |
|
|
(72,845 |
) |
|
|
(2,354 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net loss attributed to Novo Integrated Sciences, Inc. |
|
$ |
(4,805,167 |
) |
|
$ |
(1,339,870 |
) |
|
$ |
(6,611,754 |
) |
|
$ |
(2,111,340 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net loss |
|
|
(4,868,204 |
) |
|
|
(1,340,591 |
) |
|
|
(6,684,599 |
) |
|
|
(2,113,694 |
) |
|
Foreign currency translation gain |
|
|
114,738 |
|
|
|
42,232 |
|
|
|
11,205 |
|
|
|
52,828 |
|
|
Comprehensive loss: |
|
$ |
(4,753,466 |
) |
|
$ |
(1,298,359 |
) |
|
$ |
(6,673,394 |
) |
|
$ |
(2,060,866 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Weighted average common shares outstanding – basic and diluted |
|
|
28,740,700 |
|
|
|
23,754,808 |
|
|
|
27,827,686 |
|
|
|
23,630,900 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net loss per common share – basic and diluted |
|
$ |
(0.17 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.24 |
) |
|
$ |
(0.09 |
) |
|
NOVO INTEGRATED SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY For the Three and Six Months Ended February 28, 2022 and 2021 (unaudited) |
||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
||||||||||||||||||
|
|
|
|
|
|
|
Additional |
|
Common |
|
Other |
|
|
|
Novo |
|
|
|
|
||||||||||||||||||
|
|
|
Common Stock |
|
Paid-in |
|
Stock To |
|
Comprehensive |
|
Accumulated |
|
Stockholders’ |
|
Noncontrolling |
|
Total |
||||||||||||||||||||
|
|
|
Shares |
|
Amount |
|
Capital |
|
Be Issued |
|
Income |
|
Deficit |
|
Equity |
|
Interest |
|
Equity |
||||||||||||||||||
|
Balance, August 31, 2021 |
|
|
26,610,144 |
|
$ |
26,610 |
|
$ |
54,579,396 |
|
$ |
9,236,607 |
|
$ |
991,077 |
|
|
$ |
(20,969,274 |
) |
|
$ |
43,864,416 |
|
|
$ |
(60,261 |
) |
|
$ |
43,804,155 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Common stock for services |
|
|
35,000 |
|
|
|
35 |
|
|
|
64,715 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
64,750 |
|
|
|
– |
|
|
|
64,750 |
|
|
Common stock issued as collateral and held in escrow |
|
|
2,000,000 |
|
|
|
2,000 |
|
|
|
(2,000 |
) |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
Common stock to be issued for purchase of Terragenx |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
983,925 |
|
|
|
– |
|
|
|
– |
|
|
|
983,925 |
|
|
|
97,311 |
|
|
|
1,081,236 |
|
|
Common stock to be issued for purchase of Mullin assets |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
188,925 |
|
|
|
– |
|
|
|
– |
|
|
|
188,925 |
|
|
|
– |
|
|
|
188,925 |
|
|
Value of warrants issued with convertible notes |
|
|
– |
|
|
|
– |
|
|
|
295,824 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
295,824 |
|
|
|
– |
|
|
|
295,824 |
|
|
Fair value of stock options |
|
|
– |
|
|
|
– |
|
|
|
154,135 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
154,135 |
|
|
|
– |
|
|
|
154,135 |
|
|
Foreign currency translation loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(103,533 |
) |
|
|
– |
|
|
|
(103,533 |
) |
|
|
(855 |
) |
|
|
(104,388 |
) |
|
Net loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(1,806,587 |
) |
|
|
(1,806,587 |
) |
|
|
(9,808 |
) |
|
|
(1,816,395 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Balance, November 30, 2021 |
|
|
28,645,144 |
|
|
|
28,645 |
|
|
|
55,092,070 |
|
|
|
10,409,457 |
|
|
|
887,544 |
|
|
|
(22,775,861 |
) |
|
|
43,641,855 |
|
|
|
26,387 |
|
|
|
43,668,242 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Common stock for services |
|
|
240,000 |
|
|
|
240 |
|
|
|
297,760 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
298,000 |
|
|
|
– |
|
|
|
298,000 |
|
|
Value of warrants issued with convertible notes |
|
|
– |
|
|
|
– |
|
|
|
5,257,466 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
5,257,466 |
|
|
|
– |
|
|
|
5,257,466 |
|
|
Fair value of stock options |
|
|
– |
|
|
|
– |
|
|
|
44,427 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
44,427 |
|
|
|
– |
|
|
|
44,427 |
|
|
Foreign currency translation gain |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
114,738 |
|
|
|
– |
|
|
|
114,738 |
|
|
|
355 |
|
|
|
115,093 |
|
|
Net loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(4,805,167 |
) |
|
|
(4,805,167 |
) |
|
|
(63,037 |
) |
|
|
(4,868,204 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Balance, February 28, 2022 |
|
|
28,885,144 |
|
|
$ |
28,885 |
|
|
$ |
60,691,723 |
|
|
$ |
10,409,457 |
|
|
$ |
1,002,282 |
|
|
$ |
(27,581,028 |
) |
|
$ |
44,551,319 |
|
|
$ |
(36,295 |
) |
|
$ |
44,515,024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Balance, August 31, 2020 |
|
|
23,466,236 |
|
|
$ |
23,466 |
|
|
$ |
44,905,454 |
|
|
$ |
– |
|
|
$ |
1,199,696 |
|
|
$ |
(16,507,127 |
) |
|
$ |
29,621,489 |
|
|
$ |
(49,859 |
) |
|
$ |
29,571,630 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Common stock issued for cash |
|
|
21,905 |
|
|
|
22 |
|
|
|
91,978 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
92,000 |
|
|
|
– |
|
|
|
92,000 |
|
|
Common stock issued for services |
|
|
65,000 |
|
|
|
65 |
|
|
|
247,935 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
248,000 |
|
|
|
– |
|
|
|
248,000 |
|
|
Foreign currency translation gain |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
10,596 |
|
|
|
– |
|
|
|
10,596 |
|
|
|
(225 |
) |
|
|
10,371 |
|
|
Net loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(771,470 |
) |
|
|
(771,470 |
) |
|
|
(1,633 |
) |
|
|
(773,103 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Balance, November 30, 2020 |
|
|
23,553,141 |
|
|
|
23,553 |
|
|
|
45,245,367 |
|
|
|
– |
|
|
|
1,210,292 |
|
|
|
(17,278,597 |
) |
|
|
29,200,615 |
|
|
|
(51,717 |
) |
|
|
29,148,898 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Exercise of stock options |
|
|
7,500 |
|
|
|
8 |
|
|
|
11,992 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
12,000 |
|
|
|
– |
|
|
|
12,000 |
|
|
Common stock issued for intellectual property |
|
|
240,000 |
|
|
|
240 |
|
|
|
875,760 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
876,000 |
|
|
|
– |
|
|
|
876,000 |
|
|
Common stock to be issued for services rendered |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
375,000 |
|
|
|
– |
|
|
|
– |
|
|
|
375,000 |
|
|
|
– |
|
|
|
375,000 |
|
|
Rounding due to stock split |
|
|
957 |
|
|
|
1 |
|
|
|
(1 |
) |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
Fair value of vested stock options |
|
|
– |
|
|
|
– |
|
|
|
22,215 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
22,215 |
|
|
|
– |
|
|
|
22,215 |
|
|
Foreign currency translation loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
42,232 |
|
|
|
– |
|
|
|
42,232 |
|
|
|
(965 |
) |
|
|
41,267 |
|
|
Net loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(1,339,870 |
) |
|
|
(1,339,870 |
) |
|
|
(721 |
) |
|
|
(1,340,591 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Balance, February 28, 2021 |
|
|
23,801,598 |
|
|
$ |
23,802 |
|
|
$ |
46,155,333 |
|
|
$ |
375,000 |
|
|
$ |
1,252,524 |
|
|
$ |
(18,618,467 |
) |
|
$ |
29,188,192 |
|
|
$ |
(53,403 |
) |
|
$ |
29,134,789 |
|
|
NOVO INTEGRATED SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS For the Six Months Ended February 28, 2022 and 2021 (unaudited) |
||||||||
|
|
|
Six Months Ended |
||||||
|
|
|
February 28, |
|
February 28, |
||||
|
|
|
2022 |
|
2021 |
||||
|
|
|
(unaudited) |
|
(unaudited) |
||||
|
|
|
|
|
|
||||
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
||
|
Net loss |
|
$ |
(6,684,599 |
) |
|
$ |
(2,113,694 |
) |
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
||
|
Depreciation and amortization |
|
|
1,467,837 |
|
|
|
737,423 |
|
|
Fair value of vested stock options |
|
|
198,562 |
|
|
|
22,215 |
|
|
Common stock issued for services |
|
|
362,750 |
|
|
|
623,000 |
|
|
Operating lease expense |
|
|
289,626 |
|
|
|
306,717 |
|
|
Amortization of debt discount |
|
|
1,520,862 |
|
|
|
– |
|
|
Foreign currency transaction losses |
|
|
401,368 |
|
|
|
– |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
|
Accounts receivable |
|
|
213,125 |
|
|
|
353,649 |
|
|
Inventory |
|
|
46,135 |
|
|
|
– |
|
|
Prepaid expenses and other current assets |
|
|
(285,444 |
) |
|
|
(216,568 |
) |
|
Accounts payable |
|
|
(422,847 |
) |
|
|
(938 |
) |
|
Accrued expenses |
|
|
(111,479 |
) |
|
|
153,807 |
|
|
Accrued interest |
|
|
277,075 |
|
|
|
5,867 |
|
|
Operating lease liability |
|
|
(282,703 |
) |
|
|
(301,250 |
) |
|
Net cash used in operating activities |
|
|
(3,009,732 |
) |
|
|
(429,772 |
) |
|
|
|
|
|
|
|
|
||
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
||
|
Purchase of property and equipment |
|
|
(192,536 |
) |
|
|
(618 |
) |
|
Cash acquired with acquisition |
|
|
29,291 |
|
|
|
– |
|
|
Net cash used in investing activities |
|
|
(163,245 |
) |
|
|
(618 |
) |
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
||
|
Repayments to related parties |
|
|
(4,350 |
) |
|
|
(82,723 |
) |
|
Repayments of finance leases |
|
|
(10,934 |
) |
|
|
– |
|
|
Repayments of notes payable |
|
|
(4,415,000 |
) |
|
|
– |
|
|
Proceeds from the sale of common stock, net of offering costs |
|
|
– |
|
|
|
92,000 |
|
|
Proceeds from exercise of stock options |
|
|
– |
|
|
|
12,000 |
|
|
Proceeds from issuance of convertible notes, net |
|
|
15,270,000 |
|
|
|
– |
|
|
Net cash provided by financing activities |
|
|
10,839,716 |
|
|
|
21,277 |
|
|
|
|
|
|
|
|
|
||
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
(15,904 |
) |
|
|
39,832 |
|
|
|
|
|
|
|
|
|
||
|
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
|
|
7,650,835 |
|
|
|
(369,281 |
) |
|
|
|
|
|
|
|
|
||
|
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
|
|
8,293,162 |
|
|
|
2,067,718 |
|
|
|
|
|
|
|
|
|
||
|
CASH AND CASH EQUIVALENTS, END OF PERIOD |
|
$ |
15,943,997 |
|
|
$ |
1,698,437 |
|
|
|
|
|
|
|
|
|
||
|
CASH PAID FOR: |
|
|
|
|
|
|
||
|
Interest |
|
$ |
1,294,912 |
|
|
$ |
32,936 |
|
|
Income taxes |
|
$ |
– |
|
|
$ |
– |
|
|
|
|
|
|
|
|
|
||
|
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES: |
|
|
|
|
|
|
||
|
Common stock to be issued for intangible assets |
|
$ |
188,925 |
|
|
$ |
960,000 |
|
|
Common stock to be issued for acquisition |
|
$ |
983,925 |
|
|
$ |
– |
|
Contacts
Chris David, COO-President
Novo Integrated Sciences, Inc.
chris.david@novointegrated.com
(888) 512-1195
HANGZHOU, China, June 5, 2024 /PRNewswire/ -- Rokid's augmented reality (AR) devices are making significant inroads…
MCCLEAN, Va., June 5, 2024 /PRNewswire/ -- Pureture, a US biotech company specializing in developing animal-free…
HOUSTON, June 5, 2024 /PRNewswire/ -- Fullpower Technologies, in collaboration with Stanford Sleep Medicine and…
John Bostjancic Appointed as Chief Financial Officer Bob Guyatt Appointed as Senior Vice President of…
IRVINE, Calif., June 5, 2024 /PRNewswire/ -- ACS Diagnostics, Inc. of Irvine CA, with executive…
LANSING, Mich., June 5, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG), an innovative leader in…
